STAC3 as a poor prognostic biomarker in renal clear cell carcinoma: relationship with immune infiltration: Am J Cancer Res. 2024; 14(7): 3294-3316

Key Points

• STAC3 serves as a poor prognostic biomarker for renal clear cell carcinoma, affecting patient outcomes.
• Higher levels of immune infiltration correlate with poor prognostic indications linked to STAC3 expression.
• This observational analysis assessed the relationship of STAC3 with immune infiltration in renal clear cell carcinoma cases.
• These findings suggest that STAC3 may influence treatment strategies, though further validation is warranted.

Abstract